Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
作者信息
Pfeffer Marc A, Claggett Brian, Lewis Eldrin F, Granger Christopher B, Køber Lars, Maggioni Aldo P, Mann Douglas L, McMurray John J V, Rouleau Jean-Lucien, Solomon Scott D, Steg Philippe Gabriel, Berwanger Otavio, Cikes Maja, De Pasquale Carmine G, Fernandez Alberto, Filippatos Gerasimos, Jering Karola, Landmesser Ulf, Menon Venugopal, Merkely Béla, Petrie Mark C, Petrov Ivo, Schou Morten, Senni Michele, Sim David, van der Meer Peter, Lefkowitz Martin, Zhou Yinong, Wang Yi, Braunwald Eugene
机构信息
Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School Boston, MA (M.A.P., B.C., S.D.S., K.J.).
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA (E.F.L.).
出版信息
Circulation. 2022 Jan 4;145(1):87-89. doi: 10.1161/CIRCULATIONAHA.121.057429. Epub 2021 Nov 19.
Abstract
摘要
相似文献
1
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
Circulation. 2022 Jan 4;145(1):87-89. doi: 10.1161/CIRCULATIONAHA.121.057429. Epub 2021 Nov 19.
2
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Eur J Heart Fail. 2022 Oct;24(10):1918-1927. doi: 10.1002/ejhf.2663. Epub 2022 Sep 14.
3
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Circulation. 2022 Oct 4;146(14):1067-1081. doi: 10.1161/CIRCULATIONAHA.122.059210. Epub 2022 Sep 9.
4
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.
5
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
J Assoc Physicians India. 2022 Apr;70(4):11-12.
6
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.
Eur J Heart Fail. 2024 Jan;26(1):130-139. doi: 10.1002/ejhf.3079. Epub 2023 Nov 29.
7
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
Circulation. 2021 Jun 8;143(23):2316-2318. doi: 10.1161/CIRCULATIONAHA.121.054496. Epub 2021 Jun 7.
8
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Circulation. 2022 Dec 6;146(23):1749-1757. doi: 10.1161/CIRCULATIONAHA.122.060841. Epub 2022 Nov 2.
9
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
Am J Cardiol. 2021 Aug 15;153:150-152. doi: 10.1016/j.amjcard.2021.05.033. Epub 2021 Jun 29.
10
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
Circulation. 2021 Jul 13;144(2):180-182. doi: 10.1161/CIRCULATIONAHA.121.054034. Epub 2021 Jul 12.
引用本文的文献
1
Effects of angiotensin receptor-neprilysin inhibition on myocardial energy metabolism and prognosis in patients with acute myocardial infarction complicated by heart failure.
Front Cardiovasc Med. 2025 Aug 12;12:1550624. doi: 10.3389/fcvm.2025.1550624. eCollection 2025.
2
Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations).
Heart Fail Rev. 2025 Mar;30(2):387-405. doi: 10.1007/s10741-024-10471-1. Epub 2025 Jan 7.
3
Effectiveness of electronic medical record-based strategies for death and hospital admission endpoint capture in pragmatic clinical trials.
J Am Med Inform Assoc. 2025 Feb 1;32(2):349-356. doi: 10.1093/jamia/ocae303.
4
EMMY trial: What we know and what we need to know.
J Family Med Prim Care. 2024 Oct;13(10):4145-4148. doi: 10.4103/jfmpc.jfmpc_361_24. Epub 2024 Oct 18.
5
Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease.
ESC Heart Fail. 2024 Oct;11(5):3406-3415. doi: 10.1002/ehf2.14933. Epub 2024 Jul 8.
6
Assessing the early prognosis of heart failure after acute myocardial infarction using left ventricular pressure-strain loop: a prospective randomized controlled clinical study.
Quant Imaging Med Surg. 2024 Feb 1;14(2):1957-1970. doi: 10.21037/qims-23-1079. Epub 2024 Jan 23.
7
Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
ESC Heart Fail. 2024 Apr;11(2):937-949. doi: 10.1002/ehf2.14646. Epub 2024 Jan 15.
8
Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes.
NEJM Evid. 2022 Oct;1(10). doi: 10.1056/evidoa2200047. Epub 2022 Jun 30.
9
Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991-2016.
Eur J Heart Fail. 2023 Aug;25(8):1213-1224. doi: 10.1002/ejhf.2965. Epub 2023 Jul 17.
10
Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey.
J Pers Med. 2023 Jun 19;13(6):1015. doi: 10.3390/jpm13061015.
本文引用的文献
1
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.
2
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.
Eur J Heart Fail. 2021 Jun;23(6):1040-1048. doi: 10.1002/ejhf.2191. Epub 2021 Apr 22.
3
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
4
The Primary Outcome Fails - What Next?
N Engl J Med. 2016 Sep 1;375(9):861-70. doi: 10.1056/NEJMra1510064.
5
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
Zotero 插件